News

Fourth Quarter Results Net earnings were $118.1 million, against fourth quarter 2007 net earnings of $114.4 million. Excluding restructuring and other special items recorded in 2008 and 2007,

Mr Lehner reports to Marc Cluzel, senior vice president of R&D at Sanofi-Aventis. The chief medical officer will also chair the internal benefit/risk assessment committee created in 2008

The two-year project ‘drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors’ focuses on Galapagos’s novel drug targets and the candidate drugs

Antisoma and Novartis have a worldwide development and commercialization agreement for ASA404. Trials in breast cancer will be in addition to two ongoing pivotal Phase III trials in

Emergent BioSolutions has signed a marketing agreement with Biological E for the marketing of BioThrax in India. BioThrax is the only vaccine for the prevention of anthrax infection

Dr Halpern was most recently director of regulatory affairs and head of technical regulatory affairs, North America for GlaxoSmithKline Biologicals. Dr Halpern has received her bachelor’s degree in

With this acquisition, Biotest Pharmaceuticals now operates 11 plasma centers in various locations throughout the US. In 2008, the company announced it had aggressive plans for further expansion

Oral dnaJP1 is a 14 amino acid sequence delivered once daily to rheumatoid arthritis (RA patients). Oral dnaJP1 has completed a 160 patient double-blind, placebo controlled Phase II

According to the company, this position will cover all group’s business development and acquisition activities as well as corporate planning, financial and economic evaluation of internal and external